---
title: "Liaoning Oxiranchem,Inc (300082.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/300082.SZ.md"
symbol: "300082.SZ"
name: "Liaoning Oxiranchem,Inc"
industry: "Specialty Chemicals"
---

# Liaoning Oxiranchem,Inc (300082.SZ)

| Item | Detail |
|------|--------|
| Industry | Specialty Chemicals |
| Location | CN Market |
| Website | [www.oxiranchem.com](https://www.oxiranchem.com) |

## Company Profile

Liaoning Oxiranchem,Inc. engages in the research and development, production, and sale of high-end and ethylene oxide derivative fine chemicals in China and internationally. The company offers crystalline silicon cutting liquids; water reducing agents polyether; polyether monomers and polyol; ethyle...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:09.000Z

**Overall: C (0.47)**

**Industry**: Specialty Chemicals

| Metric | Value |
|--------|-------|
| Industry Ranking | 89 / 154 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.70% |  |
| Net Profit YoY | 87.02% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 2.43 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6.67B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 4.44B |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -1.17% | D |
| Profit Margin | -0.73% | D |
| Gross Margin | 6.50% | E |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.70% | B |
| Net Profit YoY | 87.02% | A |
| Total Assets YoY | 3.29% | C |
| Net Assets YoY | -1.68% | D |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -13739.20% | E |
| OCF YoY | 15.70% | B |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.81 | B |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 46.67% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Liaoning Oxiranchem,Inc",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-1.17%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-0.73%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "6.50%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "15.70%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "87.02%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.29%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-1.68%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-13739.20%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "15.70%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.81",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "46.67%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | NHU (SZ.002001) | A | B | C | B | C | B |
| 02 | HCSC (SH.600378) | B | A | B | C | B | B |
| 03 | DING LONG (SZ.300054) | B | B | C | C | B | B |
| 04 | CAPCHEM (SZ.300037) | B | B | E | A | B | B |
| 05 | Cathay Biotech (SH.688065) | C | A | D | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -206.46 | 149/157 | - | - | - |
| PB | 2.43 | 49/157 | 2.44 | 1.95 | 1.64 |
| PS (TTM) | 1.50 | 17/157 | 1.51 | 1.20 | 1.11 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-13T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 9.80 |
| Highest Target | 8.00 |
| Lowest Target | 8.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/300082.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/300082.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/300082.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.